Haleon (HLN) Total Non-Current Liabilities (2021 - 2026)
Haleon's (HLN) quarterly Total Non-Current Liabilities came in at -$13.3 billion in Q2 2026, up 11.61% on a QoQ basis from -$15.0 billion in Q4 2025.
Haleon (HLN) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Haleon (HLN) has 6 years of Total Non-Current Liabilities data on file, last reported at -$13.3 billion in Q2 2026.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to -$13.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$13.3 billion (changed N/A YoY) and the FY2025 annual result came in at -$14.9 billion, down 195.03% from the prior year.
- Total Non-Current Liabilities rose to -$13.3 billion in Q2 2026, from -$15.0 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $16.4 billion in Q4 2022 to a low of -$17.4 billion in Q2 2022.
- A 5-year average of -$3.4 billion and a median of -$13.6 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 226.04% — and 2025, when it plunged 195.32%.
- Tracing HLN's Total Non-Current Liabilities over 5 years: stood at $16.4 billion in 2022, then declined by 4.03% to $15.7 billion in 2023, then climbed by 0.09% to $15.8 billion in 2024, then slumped by 195.32% to -$15.0 billion in 2025, then gained by 11.61% to -$13.3 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at -$13.3 billion (Q2 2026), -$15.0 billion (Q4 2025), and $15.8 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 2.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.28 Bn |
| Dec 31, 2025 | -15.02 Bn |
| Dec 31, 2024 | 15.76 Bn |
| Jun 30, 2024 | -13.97 Bn |
| Dec 31, 2023 | 15.75 Bn |
| Jun 30, 2023 | -15.78 Bn |
| Dec 31, 2022 | 16.41 Bn |
| Jun 30, 2022 | -17.39 Bn |
| Dec 31, 2021 | 5.03 Bn |